Sepsis Clinical Trial
Official title:
Oxidative Monitoring in ICU Patients.
Sepsis is common in the ICU and is associated with high mortality that reaches up to 60%,
increased duration of hospitalization and additional costs [1,2].Early diagnosis and
stratification of severity are of great importance in order to timely apply proper and
adequate treatment [3].
Oxidative stress is implicated in inflammation and sepsis and sepsis severity seems to
correlate with increased oxidative stress [7,8]. Monitoring of oxidative stress has been
done so far with various markers which reflect the different pathways of oxidative stress as
is oxidosis of lipids, proteins, nucleic acids; yet the antioxidant capacity of various
enzymes and vitamins has been studied [9]. However these methods do not reflect oxidative
stress as a whole, are time consuming, need special laboratory procedures and are costly.
Oxidation-reduction potential is a new technique that enables bedside assessment of the
oxidative status. It is based on measuring the balance of oxidants and reductants in human
blood with a simple plasma test that reports results immediately.
Hypothesis
Oxidation-reduction potential, used for oxidative monitoring in ICU patients, might
correlate with sepsis severity and may be used in addition to other clinical and/or
inflammatory markers to assess severity and possibly prognosis.
4. Procedures/evaluation of the trial 4.1 Evaluation at entry
The selected oxidative parameters that will be assessed in this study will be:
oxidation-reduction potential (ORP) in plasma thiobarbituric acid-reactive substances
(TBARS) in plasma protein carbonyls (CO) in plasma total antioxidant capacity in plasma
(TAC)
The inflammatory parameters that will be measured are:
C-Reactive protein in plasma Brain Natriuretic Peptide (BNP) in whole blood Troponin-I in
whole blood Soluble CD14 subtype presepsin ( sCD14-ST) in whole blood
.2. Time of assessment Measurements will be performed within the first 24hours upon entry
and daily regarding the ORP detection and oxidative markers for a period of 10 days, if
sepsis is not present.
In the presence of sepsis diagnosis, measurements will be performed daily until the 7th day
of the septic episode plus at the time of sepsis resolution or at the point of death and at
the end of the follow-up period, on the 28th day.
For the inflammatory markers measurements will be performed as followed:
C-Reactive protein in plasma daily Brain Natriuretic Peptide (BNP) in whole blood at
admission and/or sepsis diagnosis and every 72h until resolution/death and on the 28th day.
Troponin-I in whole blood at admission and/or sepsis diagnosis and during sepsis according
to heart ultrasound findings and on the 28th day.
Soluble CD14 subtype presepsin ( sCD14-ST) in whole blood
4.3. Blood collection and store Arterial blood from an indwelling arterial catheter will be
drawn from each patient.
The blood will be kept in a tube with sodium heparin, immediately centrifuged at 1,370g and
a small portion will be used for the detection of ORP while the remaining fraction will be
collected and stored at -80o C until further analysis.
4.4. Assessment of the oxidative markers ORP will be immediately assessed using the device
RedoxSYS of Luoxis (Ampio Pharmaceuticals Inc, CO, USA) The device reports two measurements
static ORP, and capacity for every plasma sample [11 ].
For TBARS, a slightly modified assay of Keles et al. [12 ] will be used, while plasma
protein carbonyls will be determined based on the method of Patsoukis et al. [13 ]. TAC
determination will be based on a previously described method [14].
5. Data collection
Data to be recorded for each subject are:
Past medical history Patients wil be divided in medical, surgical and trauma groups.
(comprising patients with renal disease, diabetes, Chronic obstructive pulmonary disease,
coronary artery disease, immunocompromized states, cerebrovascular disease).
Data to be recorded during ICU stay for each subject, are:
APACHE II score at entry SOFA score at enry and upon all other timepoints. Sepsis severity
(sepsis, severe sepsis, septic shock), upon diagnosis and for the rest timepoints.
In all timepoints:
Oxygen concentration (FiO2), partial oxygen pressure , mode of mechanical ventilation,
static compliance, tidal volume.
Blood pH Blood lactate Levels of vasopressors and inotropes (noradrenaline, adrenaline,
dopamine, dobutamine, vasopressin. The peak dose will be recorded within the last 24h).
Temperature (peak value in the last 24h)
Every day a full blood count and biochemical examinations will take place. Data to be
recorded in all timepoints are:
Blood leukocyte count Platelets Fibrinogen Prothrombin time/Partial thromboplastin time
Urea/Creatinine Transaminases Bilirubin (total, conjugated) Uric acid Blood albumin (every 3
days).
In addition :
Surveillance cultures upon entry. Blood, bronchial secretions, urine cultures at sepsis
diagnosis and of any other fluid or tissue connected with the sepsis cause according to the
attending physician. Specimens of all cultures will be repeated during the septic episode
according to the attending physicianʼs opinion and will also be recorded.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |